Status:
COMPLETED
Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
Lead Sponsor:
Veterans Medical Research Foundation
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Patients with schizophrenia are much more likely to be engaged in smoking and other addictive behaviors, possibly related to biochemical abnormalities in the reward center of the brain. The primary pu...
Detailed Description
This is an 8 week open label trial being conducted in stable adult outpatients with schizophrenia who are smokers. The primary intervention is a switch in the subject's antipsychotic to aripiprazole, ...
Eligibility Criteria
Inclusion
- Schizophrenia, on stable antipsychotic dose for at least one month
- Ages 18-65 inclusive
- Overweight (body mass index of 25 kg/m2 or greater)
- Daily cigarette smoker (by self-report)
Exclusion
- Inability to provide informed consent
- Treatment refractory schizophrenia
- Current treatment with clozapine
- Current antipsychotic polypharmacy which may preclude monotherapy with aripiprazole
- Documented poor compliance with oral antipsychotic medication
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00167817
Start Date
July 1 2003
End Date
September 1 2005
Last Update
April 19 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA San Diego Healthcare System
San Diego, California, United States, 92161